Sharps Technology Inc (NASDAQ:STSS) shares are trading higher by 39.8% to $0.63 during Thursday’s session after the company signed a 5-year $200 million syringe sales agreement with Nephron Pharmaceuticals.
The company says the deal complements Sharps Technology’s acquisition of InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. The facility will be North America’s only dedicated COC prefillable syringe manufacturing plant, featuring advanced production capabilities.
Product delivery is set ...
STSS) Stock Is Skyrocketing>Full story available on Benzinga.com